According to a new report, published by KBV research, The Global Emphysema Treatment size is expected to reach $6.05 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.
The Steroids market is showcasing a CAGR of 6.8% during (2022 - 2028). Inhalational or oral administration of corticosteroids, such as prednisone, are both viable options for treating steroid-related conditions. In order to identify whether or not a patient has emphysema in their sputum, a physician may sometimes do tests on the patient, such as obtaining a sample of the patient's sputum. If they do, the steroid therapies may work better for them.
The Drug Stores & Retail Pharmacies market acquired maximum revenue share in the Global Emphysema Treatment Market by Distribution Channel in 2021, thereby, achieving a market value of $3.2 billion by 2028. In the emphysema treatment market in 2021, the bronchodilators segment accounted for the largest revenue share. The expansion of this market segment may be attributed to an increase in the demand for bronchodilators as a therapy for emphysema and increased knowledge about the condition.
The North America market dominated the Global Emphysema Treatment Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2.7 billion by 2028. The Europe market is registering a CAGR of 6.6% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 7.1% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/emphysema-treatment-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma PLC
By Medication Type
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
